Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Biochemistry
• Immunology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Transforming growth factor-beta1 (TGF-beta1) is a cytokine with diverse biological functions.
• The role of TGF-beta1 in ALS pathogenesis is not fully understood.

Purpose of the Study:

• To quantify plasma levels of TGF-beta1 in ALS patients.
• To compare TGF-beta1 levels between ALS patients and healthy controls.
• To explore the relationship between TGF-beta1 levels and clinical parameters in ALS.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure TGF-beta1 concentrations.
• Plasma samples were collected from 11 patients diagnosed with ALS.
• Plasma samples from 13 age-matched healthy individuals served as controls.

Main Results:

• Mean plasma TGF-beta1 concentration was significantly higher in ALS patients (2.15 ng/ml) compared to healthy controls (1.59 ng/ml) (P=0.031).
• A significant positive correlation was observed between plasma TGF-beta1 levels and the duration of illness in ALS patients (r=0.66, P=0.028).

Conclusions:

• Plasma TGF-beta1 levels are elevated in individuals with ALS.
• Increased TGF-beta1 concentration in ALS is associated with longer disease duration.
• These findings indicate that TGF-beta1 may be implicated in the disease process of ALS.